Conference Reports for NATAP

The International Liver Congress™ EASL - European Association for the Study of the Liver June 21-24 2023 Back

Evidence of durable response to bepirovirsen in B-Clear responders: B-Sure first annual report       EASL 2023 June 21-24 Vienna   EASL 2022 Efficacy and safety of bepirovirsen in patients with chronic hepatitis B virus infection: interim results from the randomised Phase 2b B-Clear study   NEJM published Nov 2022   AASLD 2022 HBV DNA and HBsAg loss with bepirovirsen monotherapy in patients with chronic hepatitis B infection not on nucleos(t)ide analogue therapy: B-Clear study end-of-study results   AASLD 2022 Bepirovirsen (BPV) in patients with chronic hepatitis B virus (HBV) infection controlled by nucleos(t)ide analogue therapy: HBV DNA and HBsAg loss 6 months after end of BPV treatment (B-Clear study)